POINT BIOPHARMA GLOBAL INC (PNT) Stock Fundamental Analysis
USA - NASDAQ:PNT - US7305411099 - Common Stock
12.5 USD
+0.02 (+0.16%)
12.51 USD
+0.01 (+0.08%)
We assign a fundamental rating of 5 out of 10 to PNT. PNT was compared to 534 industry peers in the Biotechnology industry. While PNT has a great health rating, its profitability is only average at the moment. PNT has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
PNT had positive earnings in the past year.
PNT had a positive operating cash flow in the past year.
1.2 Ratios
Looking at the Return On Assets, with a value of 20.22%, PNT belongs to the top of the industry, outperforming 99.49% of the companies in the same industry.
The Return On Equity of PNT (22.77%) is better than 97.81% of its industry peers.
With an excellent Return On Invested Capital value of 18.63%, PNT belongs to the best of the industry, outperforming 99.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.22% | ||
| ROE | 22.77% | ||
| ROIC | 18.63% |
ROA(3y)-20.26%
ROA(5y)N/A
ROE(3y)-32.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PNT has a better Profit Margin (39.62%) than 99.33% of its industry peers.
With an excellent Operating Margin value of 44.22%, PNT belongs to the best of the industry, outperforming 98.99% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 44.22% | ||
| PM (TTM) | 39.62% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so PNT is still creating some value.
Compared to 1 year ago, PNT has more shares outstanding
There is no outstanding debt for PNT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 16.90 indicates that PNT is not in any danger for bankruptcy at the moment.
PNT has a better Altman-Z score (16.90) than 91.23% of its industry peers.
The Debt to FCF ratio of PNT is 0.06, which is an excellent value as it means it would take PNT, only 0.06 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.06, PNT belongs to the top of the industry, outperforming 97.30% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that PNT is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.01, PNT is in line with its industry, outperforming 43.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.06 | ||
| Altman-Z | 16.9 |
ROIC/WACC1.67
WACC11.15%
2.3 Liquidity
A Current Ratio of 9.13 indicates that PNT has no problem at all paying its short term obligations.
With a decent Current ratio value of 9.13, PNT is doing good in the industry, outperforming 73.52% of the companies in the same industry.
A Quick Ratio of 9.13 indicates that PNT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 9.13, PNT is in the better half of the industry, outperforming 73.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.13 | ||
| Quick Ratio | 9.13 |
3. Growth
3.1 Past
PNT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 195.40%, which is quite impressive.
EPS 1Y (TTM)195.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 22.94% on average over the next years. This is a very strong growth
PNT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 72.58% yearly.
EPS Next Y9.21%
EPS Next 2Y-2.62%
EPS Next 3Y36.93%
EPS Next 5Y22.94%
Revenue Next Year-14.35%
Revenue Next 2Y21.4%
Revenue Next 3Y112.36%
Revenue Next 5Y72.58%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 15.06, the valuation of PNT can be described as correct.
PNT's Price/Earnings ratio is rather cheap when compared to the industry. PNT is cheaper than 97.47% of the companies in the same industry.
PNT is valuated rather cheaply when we compare the Price/Earnings ratio to 25.67, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for PNT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.06 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PNT is valued cheaper than 97.98% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PNT indicates a rather cheap valuation: PNT is cheaper than 97.64% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.37 | ||
| EV/EBITDA | 6.16 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PNT's earnings are expected to grow with 36.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.64
PEG (5Y)N/A
EPS Next 2Y-2.62%
EPS Next 3Y36.93%
5. Dividend
5.1 Amount
PNT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
12.5
+0.02 (+0.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.74%
Inst Owner Change0%
Ins Owners5.11%
Ins Owner Change0%
Market Cap1.33B
Revenue(TTM)243.80M
Net Income(TTM)96.60M
Analysts69.33
Price Target15.05 (20.4%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.81%
Min EPS beat(2)19.08%
Max EPS beat(2)24.55%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)312.79%
Min Revenue beat(2)211.88%
Max Revenue beat(2)413.69%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.94%
EPS NY rev (1m)0%
EPS NY rev (3m)12.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)83.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)25.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.06 | ||
| Fwd PE | N/A | ||
| P/S | 5.46 | ||
| P/FCF | 14.37 | ||
| P/OCF | 11.89 | ||
| P/B | 3.14 | ||
| P/tB | 3.14 | ||
| EV/EBITDA | 6.16 |
EPS(TTM)0.83
EY6.64%
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)0.87
FCFY6.96%
OCF(TTM)1.05
OCFY8.41%
SpS2.29
BVpS3.98
TBVpS3.98
PEG (NY)1.64
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.22% | ||
| ROE | 22.77% | ||
| ROCE | 24.56% | ||
| ROIC | 18.63% | ||
| ROICexc | 81.93% | ||
| ROICexgc | 81.93% | ||
| OM | 44.22% | ||
| PM (TTM) | 39.62% | ||
| GM | N/A | ||
| FCFM | 38.02% |
ROA(3y)-20.26%
ROA(5y)N/A
ROE(3y)-32.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.06 | ||
| Debt/EBITDA | 0.04 | ||
| Cap/Depr | 742.31% | ||
| Cap/Sales | 7.92% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 101.45% | ||
| Profit Quality | 95.96% | ||
| Current Ratio | 9.13 | ||
| Quick Ratio | 9.13 | ||
| Altman-Z | 16.9 |
F-Score6
WACC11.15%
ROIC/WACC1.67
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)195.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.54%
EPS Next Y9.21%
EPS Next 2Y-2.62%
EPS Next 3Y36.93%
EPS Next 5Y22.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-14.35%
Revenue Next 2Y21.4%
Revenue Next 3Y112.36%
Revenue Next 5Y72.58%
EBIT growth 1Y234.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.05%
EBIT Next 3Y38.92%
EBIT Next 5Y-10.32%
FCF growth 1Y261.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y371.58%
OCF growth 3YN/A
OCF growth 5YN/A
POINT BIOPHARMA GLOBAL INC / PNT FAQ
What is the ChartMill fundamental rating of POINT BIOPHARMA GLOBAL INC (PNT) stock?
ChartMill assigns a fundamental rating of 5 / 10 to PNT.
What is the valuation status for PNT stock?
ChartMill assigns a valuation rating of 5 / 10 to POINT BIOPHARMA GLOBAL INC (PNT). This can be considered as Fairly Valued.
How profitable is POINT BIOPHARMA GLOBAL INC (PNT) stock?
POINT BIOPHARMA GLOBAL INC (PNT) has a profitability rating of 4 / 10.
What are the PE and PB ratios of POINT BIOPHARMA GLOBAL INC (PNT) stock?
The Price/Earnings (PE) ratio for POINT BIOPHARMA GLOBAL INC (PNT) is 15.06 and the Price/Book (PB) ratio is 3.14.
Can you provide the financial health for PNT stock?
The financial health rating of POINT BIOPHARMA GLOBAL INC (PNT) is 8 / 10.